+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Liver Fibrosis Drugs Market by Drug Class, Mechanism of Action, Route of Administration, Distribution Channel - Global Forecast to 2030- Product Image
Liver Fibrosis Drugs Market by Drug Class, Mechanism of Action, Route of Administration, Distribution Channel - Global Forecast to 2030- Product Image
Sale

Liver Fibrosis Drugs Market by Drug Class, Mechanism of Action, Route of Administration, Distribution Channel - Global Forecast to 2030

  • PDF Icon

    Report

  • 198 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 4904956
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The liver fibrosis drugs market is evolving rapidly amid mounting clinical needs, fresh therapeutic modalities, and shifting regulatory and pricing dynamics. Senior executives require clear, actionable insights to navigate this complex landscape and capture emerging opportunities in a field shaped by innovation and policy considerations.

Market Snapshot: Liver Fibrosis Drugs Market Growth and Trajectory

The Liver Fibrosis Drugs Market grew from USD 15.57 billion in 2024 to USD 17.12 billion in 2025. It is expected to continue growing at a CAGR of 9.87%, reaching USD 27.40 billion by 2030. Market expansion is being driven by the escalating global burden of chronic liver disease, ongoing scientific advances, and a broadening portfolio of therapeutics across biologics, cell and gene therapies, and small molecule inhibitors. This growth trajectory spotlights a sector defined by emergent technology, evolving care standards, and shifting competitive strategies.

Scope & Segmentation of the Liver Fibrosis Drugs Market

  • Drug Class: Biologic therapies (monoclonal antibodies, recombinant proteins), cell therapies, gene therapies, small molecule inhibitors (natural products, synthetic compounds)
  • Mechanism of Action: ASK1 inhibitors, galectin-3 inhibitors, PPAR agonists (alpha, delta, gamma), TGF beta blockers
  • Route of Administration: Injectable (intravenous, subcutaneous), oral
  • Distribution Channel: Hospital pharmacy, online pharmacy, retail pharmacy (chain, independent)
  • Regions: Americas (United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including United Kingdom, Germany, France, Russia, and others), Asia-Pacific (including China, India, Japan, Australia, and more)
  • Leading Companies: Gilead Sciences, AbbVie, F. Hoffmann-La Roche, Bristol-Myers Squibb, Pfizer, Novartis, Takeda, Merck, Intercept Pharmaceuticals, Madrigal Pharmaceuticals

Key Takeaways for Senior Decision-Makers

  • Scientific advances such as monoclonal antibodies, gene modulation strategies, and precision cell therapies are transforming the standard of care, opening new avenues for product differentiation.
  • Segment-specific opportunities are emerging, reflecting distinct clinical profiles and access pathways for biologic, cell, gene, and small molecule-based therapies.
  • Tailored strategies are needed across regions, with the Americas emphasizing R&D investment and outcomes-based contracting, while Europe and Asia-Pacific reflect unique regulatory and payer environments.
  • Integrated approaches, including combination regimens and digital health platforms, are being considered to enhance efficacy and individualized patient management.
  • Strategic collaborations, including licensing, co-development, and research partnerships, are key levers for expanding pipelines and accessing new markets.
  • Value-based pricing and early regulatory engagement are critical for streamlined commercialization and sustainable market access.

Tariff Impact: Navigating 2025 US Changes

Planned US tariff measures will affect cost structures for raw materials, APIs, and finished biologics. Increased production expenses are anticipated for manufacturers reliant on imports, reshaping supply chains and prompting investment in domestic or nearshore bioprocessing facilities. The downstream effect may alter payer negotiations, reimbursement, and ultimately patient access, while also driving contract manufacturers to diversify their operational footprints. Early hedging strategies and proactive supplier agreements can help organizations mitigate procurement volatility and maintain competitive positioning.

Primary Keyword Focus: Liver Fibrosis Drugs Market

Remaining competitive in the liver fibrosis drugs market will depend on the ability to synthesize clinical, regulatory, and operational intelligence into timely, actionable strategies for growth and risk mitigation.

Methodology & Data Sources

This market analysis utilizes a blend of primary and secondary research, incorporating data from peer-reviewed literature, regulatory filings, patent databases, and structured interviews with key opinion leaders. Quantitative surveys and cross-validated inputs support robust insights into trends, supply chains, pricing impacts, and clinical directions.

Why This Report Matters

  • Equips leaders to anticipate and respond to scientific, regulatory, and pricing shifts shaping the liver fibrosis therapeutics landscape.
  • Delivers segment-level commercial insights aligned to real-world development, manufacturing, and access challenges.
  • Enables evidence-based investment, partnering, and risk management decisions in an evolving and opportunity-rich market.

Conclusion

Executives equipped with this targeted analysis can make informed choices regarding market entry, portfolio development, strategic partnerships, and resource allocation. Proactive, focused strategies will be vital for sustainable growth and impact in the dynamic liver fibrosis drugs sector.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Liver Fibrosis Drugs Market, by Drug Class
8.1. Introduction
8.2. Biologic Therapies
8.2.1. Monoclonal Antibodies
8.2.2. Recombinant Proteins
8.3. Cell Therapies
8.4. Gene Therapies
8.5. Small Molecule Inhibitors
8.5.1. Natural Products
8.5.2. Synthetic Compounds
9. Liver Fibrosis Drugs Market, by Mechanism of Action
9.1. Introduction
9.2. ASK1 Inhibitors
9.3. Galectin-3 Inhibitors
9.4. PPAR Agonists
9.4.1. PPAR Alpha
9.4.2. PPAR Delta
9.4.3. PPAR Gamma
9.5. TGF Beta Blockers
10. Liver Fibrosis Drugs Market, by Route of Administration
10.1. Introduction
10.2. Injectable
10.2.1. Intravenous
10.2.2. Subcutaneous
10.3. Oral
11. Liver Fibrosis Drugs Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
11.4.1. Chain Pharmacy
11.4.2. Independent Pharmacy
12. Americas Liver Fibrosis Drugs Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Liver Fibrosis Drugs Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Liver Fibrosis Drugs Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Gilead Sciences, Inc.
15.3.2. AbbVie Inc.
15.3.3. F. Hoffmann-La Roche Ltd.
15.3.4. Bristol-Myers Squibb Company
15.3.5. Pfizer Inc.
15.3.6. Novartis AG
15.3.7. Takeda Pharmaceutical Company Limited
15.3.8. Merck & Co., Inc.
15.3.9. Intercept Pharmaceuticals, Inc.
15.3.10. Madrigal Pharmaceuticals, Inc.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. LIVER FIBROSIS DRUGS MARKET MULTI-CURRENCY
FIGURE 2. LIVER FIBROSIS DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. LIVER FIBROSIS DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. LIVER FIBROSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. LIVER FIBROSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. LIVER FIBROSIS DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY CELL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY GENE THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY NATURAL PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SYNTHETIC COMPOUNDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ASK1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY GALECTIN-3 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR ALPHA, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR DELTA, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR GAMMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY TGF BETA BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 59. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 60. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2030 (USD MILLION)
TABLE 61. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 62. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 63. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2030 (USD MILLION)
TABLE 64. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 65. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 66. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 67. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 68. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 69. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2030 (USD MILLION)
TABLE 70. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 71. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 72. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2030 (USD MILLION)
TABLE 73. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 74. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 75. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 76. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2030 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2030 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 105. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 106. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2030 (USD MILLION)
TABLE 107. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 108. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 109. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2030 (USD MILLION)
TABLE 110. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 111. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 112. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 113. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 114. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 115. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2030 (USD MILLION)
TABLE 116. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 117. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 118. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2030 (USD MILLION)
TABLE 119. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 120. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 121. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 122. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 123. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 124. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2030 (USD MILLION)
TABLE 125. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 126. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 127. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2030 (USD MILLION)
TABLE 128. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 129. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 130. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 131. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 132. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 133. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2030 (USD MILLION)
TABLE 134. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 135. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 136. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2030 (USD MILLION)
TABLE 137. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 138. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 139. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 140. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 141. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 142. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2030 (USD MILLION)
TABLE 143. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 144. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 145. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2030 (USD MILLION)
TABLE 146. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 147. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 148. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 149. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 150. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 151. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2030 (USD MILLION)
TABLE 152. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 153. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 154. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2030 (USD MILLION)
TABLE 155. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 156. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 157. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 158. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 159. UNITED ARAB EMIRATES LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 160. UNITED ARAB EMIRATES LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2030 (USD MILLION)
TABLE 161. UNITED ARAB EMIRATES LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 162. UNITED ARAB EMIRATES LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 163. UNITED ARAB EMIRATES LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2030 (USD MILLION)
TABLE 164. UNITED ARAB EMIRATES LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 165. UNITED ARAB EMIRATES LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 166. UNITED ARAB EMIRATES LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 167. UNITED ARAB EMIRATES LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 168. SAUDI ARABIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 169. SAUDI ARABIA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2030 (USD MILLION)
TABLE 170. SAUDI ARABIA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 171. SAUDI ARABIA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 172. SAUDI ARABIA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2030 (USD MILLION)
TABLE 173. SAUDI ARABIA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 174. SAUDI ARABIA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 175. SAUDI ARABIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 176. SAUDI ARABIA LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 177. SOUTH AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 178. SOUTH AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2030 (USD MILLION)
TABLE 179. SOUTH AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 180. SOUTH AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 181. SOUTH AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2030 (USD MILLION)
TABLE 182. SOUTH AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 183. SOUTH AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 184. SOUTH AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 185. SOUTH AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 186. DENMARK LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 187. DENMARK LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2030 (USD MILLION)
TABLE 188. DENMARK LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 189. DENMARK LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 190. DENMARK LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2030 (USD MILLION)
TABLE 191. DENMARK LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 192. DENMARK LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 193. DENMARK LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 194. DENMARK LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 195. NETHERLANDS LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 196. NETHERLANDS LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2030 (USD MILLION)
TABLE 197. NETHERLANDS LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 198. NETHERLANDS LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 199. NETHERLANDS LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2030 (USD MILLION)
TABLE 200. NETHERLANDS LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 201. NETHERLANDS LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 202. NETHERLANDS LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 203. NETHERLANDS LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 204. QATAR LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 205. QATAR LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2030 (USD MILLION)
TABLE 206. QATAR LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 207. QATAR LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 208. QATAR LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2030 (USD MILLION)
TABLE 209. QATAR LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 210. QATAR LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 211. QATAR LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 212. QATAR LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 213. FINLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 214. FINLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2030 (USD MILLION)
TABLE 215. FINLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 216. FINLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 217. FINLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2030 (USD MILLION)
TABLE 218. FINLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 219. FINLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 220. FINLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 221. FINLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 222. SWEDEN LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 223. SWEDEN LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2030 (USD MILLION)
TABLE 224. SWEDEN LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 225. SWEDEN LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 226. SWEDEN LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2030 (USD MILLION)
TABLE 227. SWEDEN LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 228. SWEDEN LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 229. SWEDEN LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 230. SWEDEN LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 231. NIGERIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 232. NIGERIA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2030 (USD MILLION)
TABLE 233. NIGERIA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 234. NIGERIA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 235. NIGERIA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2030 (USD MILLION)
TABLE 236. NIGERIA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 237. NIGERIA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 238. NIGERIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 239. NIGERIA LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 240. EGYPT LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 241. EGYPT LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2030 (USD MILLION)
TABLE 242. EGYPT LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 243. EGYPT LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 244. EGYPT LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2030 (USD MILLION)
TABLE 245. EGYPT LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 246. EGYPT LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 247. EGYPT LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 248. EGYPT LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 249. TURKEY LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 250. TURKEY LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2030 (USD MILLION)
TABLE 251. TURKEY LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 252. TURKEY LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 253. TURKEY LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2030 (USD MILLION)
TABLE 254. TURKEY LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 255. TURKEY LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 256. TURKEY LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 257. TURKEY LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 258. ISRAEL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 259. ISRAEL LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2030 (USD MILLION)
TABLE 260. ISRAEL LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 261. ISRAEL LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 262. ISRAEL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2030 (USD MILLION)
TABLE 263. ISRAEL LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 264. ISRAEL LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 265. ISRAEL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 266. ISRAEL LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 267. NORWAY LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 268. NORWAY LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2030 (USD MILLION)
TABLE 269. NORWAY LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 270. NORWAY LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 271. NORWAY LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2030 (USD MILLION)
TABLE 272. NORWAY LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 273. NORWAY LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 274. NORWAY LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 275. NORWAY LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 276. POLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 277. POLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2030 (USD MILLION)
TABLE 278. POLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 279. POLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 280. POLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2030 (USD MILLION)
TABLE 281. POLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 282. POLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 283. POLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 284. POLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 285. SWITZERLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 286. SWITZERLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2030 (USD MILLION)
TABLE 287. SWITZERLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 288. SWITZERLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 289. SWITZERLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2030 (USD MILLION)
TABLE 290. SWITZERLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 291. SWITZERLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 292. SWITZERLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 293. SWITZERLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 294. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 295. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2030 (USD MILLION)
TABLE 296. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 297. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 298. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2030 (USD MILLION)
TABLE 299. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 300. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 301. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 302. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 303. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 304. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 305. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2030 (USD MILLION)
TABLE 306. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 307. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 308. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2030 (USD MILLION)
TABLE 309. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 310. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 311. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 312. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 313. INDIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 314. INDIA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2030 (USD MILLION)
TABLE 315. INDIA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 316. INDIA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 317. INDIA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2030 (USD MILLION)
TABLE 318. INDIA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 319. INDIA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 320. INDIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 321. INDIA LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 322. JAPAN LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 323. JAPAN LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2030 (USD MILLION)
TABLE 324. JAPAN LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 325. JAPAN LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 326. JAPAN LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2030 (USD MILLION)
TABLE 327. JAPAN LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLI

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Liver Fibrosis Drugs market report include:
  • Gilead Sciences, Inc.
  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd.
  • Bristol-Myers Squibb Company
  • Pfizer Inc.
  • Novartis AG
  • Takeda Pharmaceutical Company Limited
  • Merck & Co., Inc.
  • Intercept Pharmaceuticals, Inc.
  • Madrigal Pharmaceuticals, Inc.

Table Information

Report AttributeDetails
No. of Pages198
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 17.12 Billion
Forecasted Market Value ( USD ) by 2030 $ 27.4 Billion
Compound Annual Growth Rate9.8%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Liver Fibrosis Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Liver Fibrosis Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 185 Pages
  • Global
From
Liver Fibrosis Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Liver Fibrosis Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 105 Pages
  • Global
From
Liver Fibrosis Market - Product Image

Liver Fibrosis Market

  • Report
  • 250 Pages
  • Global
From
Liver Fibrosis- Pipeline Insight, 2025 - Product Image

Liver Fibrosis- Pipeline Insight, 2025

  • Drug Pipelines
  • 85 Pages
  • Global
From
Non-Alcoholic Steatohepatitis (NASH) - Pipeline Insight, 2025 - Product Image

Non-Alcoholic Steatohepatitis (NASH) - Pipeline Insight, 2025

  • Clinical Trials
  • 240 Pages
  • Global
From

About the Liver Fibrosis Drug Market

The Liver Fibrosis Drug market is a subset of the pharmaceutical industry focused on the development of treatments for liver fibrosis. Clinical trials are a key component of the development process, as they provide evidence of the safety and efficacy of a drug. Clinical trials are conducted in phases, with each phase providing increasingly detailed information about the drug's effects. The first phase of a clinical trial typically involves a small number of participants and is designed to assess the safety of the drug. Subsequent phases involve larger numbers of participants and are designed to assess the efficacy of the drug. The Liver Fibrosis Drug market is highly competitive, with many companies vying for a share of the market. Companies in the market include Gilead Sciences, Merck, Novartis, Pfizer, and Roche. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.